HLB Therapeutics Co.,Ltd.

Equities

A115450

KR7115450009

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
9,340 KRW -5.56% Intraday chart for HLB Therapeutics Co.,Ltd. -11.89% +113.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HLB Therapeutics Co.,Ltd. announced that it has received KRW 29.99999658 billion in funding from HLB Co., Ltd. CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
HLB Life Science Co., Ltd. announced that it has received KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd. CI
HLB Life Science Co., Ltd. announced that it expects to receive KRW 8.3 billion in funding from HLB Therapeutics Co.,Ltd. CI
Panagene Inc. announced that it expects to receive KRW 56.599994061 billion in funding from a group of investors CI
Panagene Inc. announced that it expects to receive KRW 46.068324061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd. CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 2.5 billion in funding CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 5 billion in funding CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors CI
Oblato, Inc. announced that it has received KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd. CI
Oblato, Inc. announced that it expects to receive KRW 18.408 billion in funding from HLB Therapeutics Co.,Ltd. CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors CI
HLB Therapeutics Co.,Ltd. announced that it has received KRW 13.0088 billion in funding from HLB Co., Ltd. CI
HLB Therapeutics to Raise 13 Billion Won via Stock Sale MT
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 13.0088 billion in funding from HLB Co., Ltd. CI
HLB Therapeutics Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
HLB Therapeutics Submits Phase 3 Protocol for Neurotrophic Keratopathy CI
HLB Therapeutics Signs Letter of Intent with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors CI
G-treeBNT Co., Ltd. announced that it has received KRW 10 billion in funding from Shinhan Investment Corp., BFA Co.,Ltd., Bayside Private Equity CI
G-Tree Holdings Co.,Ltd. completed the acquisition of 2.65% stake in G-treeBNT Co., Ltd. from Yang Won-seok for KRW 16.9 billion. CI
Chart HLB Therapeutics Co.,Ltd.
More charts
HLB Therapeutics Co Ltd, formerly G-treeBNT Co Ltd, is a Korea-based company engaged in the research and development of optimized multimedia software for various digital appliances including cellular phones. Along with its affiliates, the Company operates solution business segment, which provides embedded graphic user interface (GUI) software solutions as well as wired and wireless integration multimedia platform solutions. Its embedded GUI products include FXUI-two-dimensional (2D), FXUI-three-dimensional (3D) and FX Studio, which are used for cellular phones and embedded equipment. Its wired and wireless integration multimedia platform products include FX-Flash and others, which are used for cellular phones and other mobile devices; electronic components manufacturing business segment, which provides transformers, pumps, motors and others, as well as educational and bio pharmaceutical business segments.
More about the company
  1. Stock Market
  2. Equities
  3. A115450 Stock
  4. News HLB Therapeutics Co.,Ltd.
  5. HLB Therapeutics to Raise 13 Billion Won via Stock Sale
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW